|
|
|
LifeScienceHistory.com - Check us out on Instagram
Massachusetts Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing MassachusettsLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Paratek Pharmaceuticals, Inc.
| | | Phone: | (617) 275-0040 | Fax: | (617) 275-0039 | Year Established: | 1996 | Ticker: | PRTK | Exchange: | NASDAQ | Main Contact: | Adam Woodrow, CCO | | Other Contacts: | Stephen Villano, M.D., VP, Clinical and Medical Affairs Jeanne Jew, Senior VP, Business Development Evan Tzanis, Senior VP, Clinical Development & Clinical Operations William Haskel, Senior VP & General Counsel Sean Johnston, M.B.A., Ph.D., VP, Manufacturing Susan Perkins, J.D., VP, IP S. Ken Tanaka, Ph.D, VP, R&D Yulii Bogatyrenko, Senior VP, Business Development Randy Brenner, Senior VP, Regulatory & Quality Evan Loh, M.D., President & COO Douglas W. Pagán, CFO Michael F. Bigham, CEO & Chairman
| | Company Description | Paratek (formerly Transcept Pharmaceuticals and Novacea) is a biopharmaceutical company focused on the development, and commercialization of innovative antibiotics. Paratek’s lead product candidate, omadacycline, is a novel tetracyclinederived,
broad-spectrum antibiotic being developed in both oral tablet and intravenous
formulations for use as a first-line monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections (UTI) and other serious community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians. Omadacycline has received Qualified Infectious Disease Product (QIDP) designation by the U.S. Food and Drug Administration for both the oral and intravenous formulations in all three of these infectious 4 disease categories. Omadacycline has Special Protocol Assessment agreements with the U.S. Food and Drug Administration for the phase 3 trials planned in ABSSSI and CABP. | |
|
|
|
|
|